Exchange: NASDAQ·Updated 07:30 PM EST

LUNG News

News
all
press releases
Pulmonx: 3 Key Takeaways for Long-Term Investors
Key PointsPulmonx returned to top-line growth with $22.8 million in third-quarter revenue...
Nasdaq News: Markets
Pulmonx: 3 Key Takeaways for Long-Term Investors
Key PointsPulmonx returned to top-line growth with $22.8 million in third-quarter revenue...
Nasdaq News: Markets
More News
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Pulmonx (NASDAQ:LUNG) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...
Benzinga
Pulmonx (LUNG) delivered earnings and revenue surprises of +26.92% and +3.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG) stock increasedread more...
Benzinga
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks

Advertisement|Remove ads.